COMP <GO>
EMN vs ALB // REVENUE GROWTH (YOY)
Eastman Chemical Company (NYSE) VS. Albemarle Corporation (NYSE) • 15-METRIC TALLY: EMN 9
— ALB 3
▲ REVENUE GROWTH (YOY) LEADER: ALB
LAST: $66.53 (-2.06%) • MKT CAP: $7.77B
revenue-growth
-6.70%
LAST: $91.00 (-2.43%) • MKT CAP: $11.01B
revenue-growth
-4.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EMN VS. ALB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EMN | ALB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.10% | 13.00% | +8.10 | EMN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | -2.60% | +7.40 | EMN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.46% | 6.29% | -0.83 | ALB | /fcf-yield <GO> |
| Operating Margin | 6.60% | -7.10% | +13.70 | EMN | /operating-margins <GO> |
| Net Profit Margin | 5.40% | -9.90% | +15.30 | EMN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -6.70% | -4.40% | -2.30 | ALB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.90% | 1.73% | +3.17 | EMN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.28 | 1.64 | +0.64 | EMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.3 | 37.3 | +23.00 | EMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.01 | +0.05 | EMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.3x | 20.0x | -4.70 | EMN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.77B | $11.01B | -$3.24B | ALB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EMN REV | ALB REV | EMN GROSS % | ALB GROSS % | EMN FCF | ALB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.75B | $5.14B | 21.1% | 13.0% | $424.0M | $692.5M |
| FY 2024 | $9.38B | $5.38B | 24.4% | 1.2% | $688.0M | -$992.7M |
| FY 2023 | $9.21B | $9.62B | — | — | $959.5M | $893.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EMN // BETA 1.06
ALB // BETA 1.01